Prelude Therapeutics annual debt-to-assets ratio
2019
2021
2022
2023
2024
2025
Prelude Therapeutics Debt-to-Assets Ratio Growth & History (PRLD)
Prelude Therapeutics's debt-to-assets ratio was 0.13 for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.13 | 0.02 | +22.58% |
| 2024 | 2024-12-31 | 0.10 | 0.04 | +68.85% |
| 2023 | 2023-12-31 | 0.06 | 0.05 | +632.05% |
| 2022 | 2022-12-31 | 0.01 | 0.00 | +45.68% |
| 2021 | 2021-12-31 | 0.01 | — | — |
| 2019 | 2019-12-31 | 0.01 | — | — |
Prelude Therapeutics quarterly debt-to-assets ratio
Q4.19
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.09 | −0.06 | −40.22% |
| Q1 2026 | 2026-03-31 | 0.15 | 0.02 | +16.76% |
| Q4 2025 | 2025-12-31 | 0.13 | 0.02 | +22.58% |
| Q3 2025 | 2025-09-30 | 0.19 | 0.10 | +104.90% |
| Q2 2025 | 2025-06-30 | 0.16 | 0.07 | +92.10% |
| Q1 2025 | 2025-03-31 | 0.13 | 0.06 | +77.71% |
| Q4 2024 | 2024-12-31 | 0.10 | 0.04 | +68.85% |
| Q3 2024 | 2024-09-30 | 0.09 | 0.09 | +4904.68% |
| Q2 2024 | 2024-06-30 | 0.08 | 0.08 | +2328.05% |
| Q1 2024 | 2024-03-31 | 0.07 | 0.06 | +918.51% |
| Q4 2023 | 2023-12-31 | 0.06 | 0.05 | +632.05% |
| Q3 2023 | 2023-09-30 | 0.00 | −0.00 | −67.92% |
| Q2 2023 | 2023-06-30 | 0.00 | −0.00 | −52.47% |
| Q1 2023 | 2023-03-31 | 0.01 | −0.00 | −12.53% |
| Q4 2022 | 2022-12-31 | 0.01 | 0.00 | +45.68% |
| Q3 2022 | 2022-09-30 | 0.01 | −0.00 | −11.68% |
| Q2 2022 | 2022-06-30 | 0.01 | 0.00 | +26.35% |
| Q1 2022 | 2022-03-31 | 0.01 | 0.00 | +32.12% |
| Q4 2021 | 2021-12-31 | 0.01 | — | — |
| Q3 2021 | 2021-09-30 | 0.01 | — | — |
| Q2 2021 | 2021-06-30 | 0.01 | — | — |
| Q1 2021 | 2021-03-31 | 0.01 | — | — |
| Q4 2019 | 2019-12-31 | 0.01 | — | — |
Prelude Therapeutics debt-to-assets ratio trends
Between the periods ended 2019-12-31 and 2025-12-31, Prelude Therapeutics's debt-to-assets ratio increased from 0.01 to 0.13, a change of 0.11. The latest reported quarter, Q2 2026, shows 0.09.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...